J&J’s Veridex To Lead Development Of Next-Gen Cancer Diagnostic

Johnson & Johnson subsidiary Veridex will partner with Massachusetts General Hospital to help bring a next-generation cancer blood test to market, both institutions announced Jan. 3.

More from Archive

More from Medtech Insight